The COMPASS study... From start to stop.

29 August 2017 (15:50 - 16:00)

Organised by:

About the speakers

Doctor Stuart J Connolly

McMaster University, Hamilton (Canada)

Doctor John William Eikelboom

McMaster University, Hamilton (Canada)

3 More presentations in this session

Opening remarks - Vascular protection in CAD and PAD through factor Xa inhibition... The COMPASS study.

Doctor S. Yusuf (Hamilton, CA)

Interactive discussions and questions - Vascular protection in CAD and PAD through factor Xa inhibition... The COMPASS study.

Professor D. Bhatt (New York City, US) Professor P. Steg (Paris, FR) Doctor S. Connolly (Hamilton, CA) Doctor S. Yusuf (Hamilton, CA) Doctor J. Eikelboom (Hamilton, CA)

Closing remarks - Vascular protection in CAD and PAD through factor Xa inhibition... The COMPASS study.

Doctor S. Connolly (Hamilton, CA) Doctor J. Eikelboom (Hamilton, CA)

Access the full session

Vascular protection in coronary artery disease (CAD) and peripheral artery disease (PAD) through factor Xa inhibition... The COMPASS study

The Event

ESC Congress 2017

29 August 2017 15:50 CET

You may be interested in

Congress Presentation

Clopidogrel following 1-month aspirin-free low-dose prasugrel monotherapy versus aspirin following 1-month DAPT after PCI for patients with ACS or HBR: Final 1-year results from the STOPDAPT-3

31 August 2024

Congress Presentation

Use of risk score to identify lower and higher risk subsets among COMPASS-Eligible patients with stable CAD. Insights from the CLARIFY Registry

3 September 2019

Congress Presentation

UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)

28 August 2022

Congress Session

HFA clinical trial course in a nutshell

17 May 2025

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

ESC 365 is supported by

Explore sponsored resources